4880 Trademark

Trademark Overview

On Thursday, September 29, 2022, a trademark application was filed for 4880 with the United States Patent and Trademark Office. The USPTO has given the 4880 trademark a serial number of 97613272. The federal status of this trademark filing is REGISTERED as of Tuesday, October 14, 2025. This trademark is owned by Mallinckrodt Pharmaceuticals Ireland Limited. The 4880 trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations, namely, nitric oxide for inhalation for treating pulmonary hypertension and conditions associated with pulmonary hypertension
4880

General Information

Serial Number97613272
Word Mark4880
Filing DateThursday, September 29, 2022
Status700 - REGISTERED
Status DateTuesday, October 14, 2025
Registration Number7986110
Registration DateTuesday, October 14, 2025
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, November 14, 2023

Trademark Statements

Goods and ServicesPharmaceutical preparations, namely, nitric oxide for inhalation for treating pulmonary hypertension and conditions associated with pulmonary hypertension

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateMonday, October 3, 2022
Primary Code005
First Use Anywhere DateThursday, March 7, 2024
First Use In Commerce DateThursday, March 7, 2024

Trademark Owner History

Party NameMallinckrodt Pharmaceuticals Ireland Limited
Party Type30 - Original Registrant
Legal Entity Type99 - Other
AddressDublin 15 D15TX2V
IE
Party NameMallinckrodt Pharmaceuticals Ireland Limited
Party Type20 - Owner at Publication
Legal Entity Type99 - Other
AddressDublin 15 D15TX2V
IE
Party NameMallinckrodt Pharmaceuticals Ireland Limited
Party Type10 - Original Applicant
Legal Entity Type99 - Other
AddressDublin 15 D15TX2V
IE

Trademark Events

Event DateEvent Description
Monday, October 3, 2022NEW APPLICATION ENTERED
Monday, October 3, 2022NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Thursday, July 13, 2023ASSIGNED TO EXAMINER
Thursday, July 13, 2023NON-FINAL ACTION WRITTEN
Thursday, July 13, 2023NON-FINAL ACTION E-MAILED
Thursday, July 13, 2023NOTIFICATION OF NON-FINAL ACTION E-MAILED
Wednesday, October 11, 2023TEAS RESPONSE TO OFFICE ACTION RECEIVED
Wednesday, October 11, 2023CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, October 11, 2023TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, October 12, 2023APPROVED FOR PUB - PRINCIPAL REGISTER
Tuesday, November 14, 2023OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Wednesday, October 25, 2023NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, November 14, 2023PUBLISHED FOR OPPOSITION
Tuesday, January 9, 2024NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Monday, July 8, 2024SOU TEAS EXTENSION RECEIVED
Monday, July 8, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, July 8, 2024SOU EXTENSION 1 FILED
Monday, January 6, 2025SOU EXTENSION 2 FILED
Monday, April 28, 2025USE AMENDMENT FILED
Saturday, September 20, 2025STATEMENT OF USE PROCESSING COMPLETE
Monday, July 8, 2024SOU EXTENSION 1 GRANTED
Monday, January 6, 2025SOU TEAS EXTENSION RECEIVED
Monday, January 6, 2025SOU EXTENSION 2 GRANTED
Monday, March 3, 2025NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, April 28, 2025TEAS STATEMENT OF USE RECEIVED
Tuesday, September 23, 2025ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Tuesday, September 23, 2025NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Tuesday, October 14, 2025REGISTERED-PRINCIPAL REGISTER
Tuesday, October 14, 2025NOTICE OF REGISTRATION CONFIRMATION EMAILED
Saturday, September 20, 2025CASE ASSIGNED TO INTENT TO USE PARALEGAL

Related Keywords

pulmonary hypertension conditions associated treating inhalation preparations namely nitric oxide